DOP2022000031A - [1,2,4]triazolo[1,5-c]quinazolin-5-aminas - Google Patents

[1,2,4]triazolo[1,5-c]quinazolin-5-aminas

Info

Publication number
DOP2022000031A
DOP2022000031A DO2022000031A DO2022000031A DOP2022000031A DO P2022000031 A DOP2022000031 A DO P2022000031A DO 2022000031 A DO2022000031 A DO 2022000031A DO 2022000031 A DO2022000031 A DO 2022000031A DO P2022000031 A DOP2022000031 A DO P2022000031A
Authority
DO
Dominican Republic
Prior art keywords
compounds
preparation
quinazolin
triazolo
pharmaceutical compositions
Prior art date
Application number
DO2022000031A
Other languages
English (en)
Spanish (es)
Inventor
Buchmann Bernd
Bothe Ulrich
Schmees Norbert
Bader Benjamin
Zorn Ludwig
Günther Judith
Platten Michael
Lefranc Julien
Michael Meier Robin
Anthony Herbert Simon
Röse Lars
Stöckigt Detlef
Gorjánácz Matyás
Kober Christina
BÖHME Stephan
Baumann Daniel
Gutcher Llona
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of DOP2022000031A publication Critical patent/DOP2022000031A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DO2022000031A 2019-08-12 2022-02-07 [1,2,4]triazolo[1,5-c]quinazolin-5-aminas DOP2022000031A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19191299 2019-08-12
EP20167707 2020-04-02
PCT/EP2020/072377 WO2021028382A1 (en) 2019-08-12 2020-08-10 [1,2,4]triazolo[1,5-c]quinazolin-5-amines

Publications (1)

Publication Number Publication Date
DOP2022000031A true DOP2022000031A (es) 2022-03-15

Family

ID=72243077

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000031A DOP2022000031A (es) 2019-08-12 2022-02-07 [1,2,4]triazolo[1,5-c]quinazolin-5-aminas

Country Status (19)

Country Link
US (1) US20230113037A1 (ja)
EP (1) EP4013508A1 (ja)
JP (1) JP2022544952A (ja)
KR (1) KR20220045978A (ja)
CN (1) CN114466850A (ja)
AU (1) AU2020328154A1 (ja)
BR (1) BR112022001628A2 (ja)
CA (1) CA3150544A1 (ja)
CO (1) CO2022001257A2 (ja)
CR (1) CR20220064A (ja)
DO (1) DOP2022000031A (ja)
EC (1) ECSP22009803A (ja)
GE (1) GEP20247611B (ja)
IL (1) IL290445A (ja)
JO (1) JOP20220034A1 (ja)
MX (1) MX2022001803A (ja)
PE (1) PE20220967A1 (ja)
TW (1) TW202126655A (ja)
WO (1) WO2021028382A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115697979A (zh) 2020-04-24 2023-02-03 拜耳公司 作为用于免疫激活的dgkzeta抑制剂的取代的氨基噻唑类
WO2022049253A1 (en) * 2020-09-07 2022-03-10 Bayer Aktiengesellschaft Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN114621236B (zh) * 2022-04-25 2024-06-18 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358964B1 (en) 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
WO2007040565A2 (en) * 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CN107648216B (zh) * 2010-07-27 2021-03-30 波士顿大学管理委员会 作为新型癌症疗法的芳烃受体(AhR)调节剂
MX2021005662A (es) * 2018-11-14 2021-10-13 Broad Inst Inc Compuestos activadores del receptor de aril hidrocarburo (ahr) como agentes terapéuticos para el cáncer.

Also Published As

Publication number Publication date
AU2020328154A1 (en) 2022-03-03
BR112022001628A2 (pt) 2022-06-21
CO2022001257A2 (es) 2022-03-08
CA3150544A1 (en) 2021-02-18
WO2021028382A1 (en) 2021-02-18
IL290445A (en) 2022-04-01
KR20220045978A (ko) 2022-04-13
US20230113037A1 (en) 2023-04-13
MX2022001803A (es) 2022-03-11
ECSP22009803A (es) 2022-03-31
JP2022544952A (ja) 2022-10-24
CN114466850A (zh) 2022-05-10
PE20220967A1 (es) 2022-06-10
EP4013508A1 (en) 2022-06-22
GEP20247611B (en) 2024-03-11
JOP20220034A1 (ar) 2023-01-30
TW202126655A (zh) 2021-07-16
CR20220064A (es) 2022-05-04

Similar Documents

Publication Publication Date Title
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
DOP2022000031A (es) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CR20180556A (es) 3-oxo-2, 6-difenil-2,3-dihidropiridazin-4-carboxamidas
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
DOP2019000117A (es) Nuevos derivados de quinolina
UY37201A (es) Nuevos derivados de pirazolopirimidina
UY37149A (es) 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas
CO2019014484A2 (es) Nuevos derivados de azaquinolina
CU23366B7 (es) Oxazolidinonas substituidas para terapia de combinación
CO2020001242A2 (es) Dihidrooxadiazinonas
UY37971A (es) Derivados de indol macrocíclicos sustituidos
MX2022006466A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune.
CO2022014876A2 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
CL2020002891A1 (es) Nuevos derivados de quinolina
UY37705A (es) Nuevos derivados de pirazol bicíclicos
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
ECSP23077322A (es) Derivados de fósforo como nuevos inhibidores de sos1
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina